20 citations
,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” This review summarizes recent research and patents on 17β-HSD3, 17β-HSD5, and 3α-HSD3 inhibitors, suggesting their potential in treating androgen-dependent diseases, but reports no new clinical results.
This invention reports piperazine derivatives as potent inhibitors of type 3 17β-hydroxysteroid dehydrogenase, suggesting potential therapeutic applications in treating prostate cancer, acne, and androgenic alopecia.
12 citations
,
March 2017 in “Medicinal Chemistry Research” This study found that certain curcumin analogs derived from natural plant sources exhibit anti-androgen activity by inhibiting steroid 5-alpha reductase, identifying key structural features for their potency and safety in treating androgen-related conditions.
46 citations
,
August 2006 in “PubMed” In this study, researchers identified and examined males with 17 beta-HSD3 deficiency in a highly inbred Arab population, noting genetic findings and the progression of male characteristics despite being raised as females initially.
115 citations
,
March 2001 in “Baillière's best practice and research in clinical endocrinology and metabolism/Baillière's best practice & research. Clinical endocrinology & metabolism” This article reviews how different 5alpha-reductase and 3alpha-HSD enzymes impact androgen levels and highlights their potential as drug targets for androgen-related diseases, but provides no new experimental findings.